Evidence map›Paper›PMID 25998963›Full record

ReviewNature reviews. Immunology2015

Perforin and granzymes: function, dysfunction and human pathology.

Ilia Voskoboinik, James C Whisstock, Joseph A Trapani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 722 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
722citing papers in PubMed, 4 pooled it
36.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

722 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Granzyme B PET Imaging Reveals LgmnAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

662 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ilia Voskoboinik
James C Whisstock
Joseph A Trapani
Peter MacCallum Cancer Centre · AUAustralian Research Council · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A defining property of cytotoxic lymphocytes is their expression and regulated secretion of potent toxins, including the pore-forming protein perforin and serine protease granzymes. Until recently, mechanisms of pore formation and granzyme transfer into the target cell were poorly understood, but advances in structural and cellular biology have now begun to unravel how synergy between perforin and granzymes brings about target cell death. These and other advances are demonstrating the surprisingly broad pathophysiological roles of the perforin–granzyme pathway, and this has important implications for understanding immune homeostasis and for developing immunotherapies for cancer and other diseases. In particular, we are beginning to define and understand a range of human diseases that are associated with a failure to deliver active perforin to target cells. In this Review, we discuss the current understanding of the structural, cellular and clinical aspects of perforin and granzyme biology.

Indexed as

AnimalsApoptosisCell CommunicationCytosolEndosomesExocytosisGranzymesHumansImmune System DiseasesInfectionsInflammationKiller Cells, NaturalNeoplasmsPerforinPolymorphism, GeneticSecretory VesiclesGranzymesPerforin

Identifiers

PMID25998963
OpenAlexW1516464304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.